Literature DB >> 28567717

ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design.

Leon J DeLalio1,2, Brant E Isakson1,3.   

Abstract

LINKED ARTICLES: This article is a Commentary on Boengler K, Bulic M, Schreckenberg R, Schlüter K-D, Schulz R (2017). The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. Br J Pharmacol 174: 2060-2073. https://doi.org/10.1111/bph.13804.
© 2017 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28567717      PMCID： PMC5513857          DOI： 10.1111/bph.13891

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  7 in total

1.  Retraction for Rottlaender et al., "Glycogen synthase kinase 3β transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels".

Authors:  Dennis Rottlaender; Kerstin Boengler; Martin Wolny; Astrid Schwaiger; Lukas J Motloch; Michel Ovize; Rainer Schulz; Gerd Heusch; Uta C Hoppe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

2.  The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43.

Authors:  Kerstin Boengler; Marko Bulic; Rolf Schreckenberg; Klaus-Dieter Schlüter; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

Review 3.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

4.  Glycogen synthase kinase 3β transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels.

Authors:  Dennis Rottlaender; Kerstin Boengler; Martin Wolny; Astrid Schwaiger; Lukas J Motloch; Michel Ovize; Rainer Schulz; Gerd Heusch; Uta C Hoppe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-11       Impact factor: 11.205

5.  The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs.

Authors:  Andreas Skyschally; Barbara Walter; Rie Schultz Hansen; Gerd Heusch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-09       Impact factor: 3.000

Review 6.  Next-Generation Connexin and Pannexin Cell Biology.

Authors:  Jessica L Esseltine; Dale W Laird
Journal:  Trends Cell Biol       Date:  2016-06-21       Impact factor: 20.808

Review 7.  Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.

Authors:  Anne Louise Kjølbye; Ketil Haugan; James K Hennan; Jørgen S Petersen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-10       Impact factor: 4.080
  7 in total
  1 in total

Review 1.  Mechanisms of Connexin Regulating Peptides.

Authors:  D Ryan King; Meghan W Sedovy; Xinyan Leng; Jianxiang Xue; Samy Lamouille; Michael Koval; Brant E Isakson; Scott R Johnstone
Journal:  Int J Mol Sci       Date:  2021-09-22       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.